Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph⁺ CML

Clin Cancer Res (2016) 22 (8): 2051–2061.

https://doi.org/10.1158/1078-0432.CCR-15-0767

Published: 14 April 2016

View article titled, Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph<sup>+</sup> CML

Includes: Supplementary data

Journal Articles

Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors

Caroline Bruenner-Kubath, Waheed Shabbir, Victoria Saferding, Renate Wagner, Christian F. Singer, Peter Valent, Walter Berger, Brigitte Marian, Christoph C. Zielinski, Michael Grusch, Thomas W. Grunt

Clin Cancer Res (2010) 16 (7_Supplement): A5.

https://doi.org/10.1158/1078-0432.TCME10-A5

Published: 02 February 2016

View article titled, Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors

Journal Articles

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herndlhofer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sperr, Matthias Mayerhofer, Thomas Rülicke, Peter Valent

Clin Cancer Res (2014) 20 (13): 3589–3602.

https://doi.org/10.1158/1078-0432.CCR-13-2811

Published: 30 June 2014

View article titled, Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

Includes: Supplementary data

Journal Articles

Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Wolfgang R. Sperr, Johannes Drach, Alexander W. Hauswirth, Jutta Ackermann, Margit Mitterbauer, Gerlinde Mitterbauer, Manuela Foedinger, Christa Fonatsch, Ingrid Simonitsch-Klupp, Peter Kalhs, Peter Valent

Clin Cancer Res (2005) 11 (19): 6787–6792.

https://doi.org/10.1158/1078-0432.CCR-05-1064

Published: 03 October 2005

View article titled, Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Journal Articles

Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse

Wolfgang R. Sperr, Margit Mitterbauer, Gerlinde Mitterbauer, Michael Kundi, Ulrich Jäger, Klaus Lechner, Peter Valent

Clin Cancer Res (2005) 11 (18): 6536–6543.

https://doi.org/10.1158/1078-0432.CCR-05-0732

Published: 15 September 2005

View article titled, Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse

Journal Articles

A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 × 1 g/m² on Days 1, 3, and 5)

Wolfgang R. Sperr, Maria Piribauer, Friedrich Wimazal, Christa Fonatsch, Renate Thalhammer-Scherrer, Ilse Schwarzinger, Klaus Geissler, Paul Knöbl, Ulrich Jäger, Klaus Lechner, Peter Valent

Clin Cancer Res (2004) 10 (12): 3965–3971.

https://doi.org/10.1158/1078-0432.CCR-04-0185

Published: 24 June 2004

View article titled, A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: <subtitle>Intermediate Dose Cytarabine (2 × 1 g/m<sup>2</sup> on Days 1, 3, and 5)</subtitle>

NARROW

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph⁺ CML

Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse

A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 × 1 g/m² on Days 1, 3, and 5)

Email alerts

AACR Journals

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation

Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse

A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 × 1 g/m2 on Days 1, 3, and 5)

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph⁺ CML

A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 × 1 g/m² on Days 1, 3, and 5)